Contrasting Pheton (NASDAQ:PTHL) and Oncology Institute (NASDAQ:TOI)

Pheton (NASDAQ:PTHL) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Volatility and Risk

Pheton has a beta of 5.4, suggesting that its share price is 440% more volatile than the S&P 500. Comparatively, Oncology Institute has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500.

Institutional & Insider Ownership

36.9% of Oncology Institute shares are owned by institutional investors. 8.5% of Oncology Institute shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Pheton and Oncology Institute”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pheton	$305,215.00	7.65	-$660,000.00	N/A	N/A
Oncology Institute	$393.41 million	0.65	-$64.66 million	($0.64)	-4.08

Pheton has higher earnings, but lower revenue than Oncology Institute.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Pheton and Oncology Institute, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pheton	1	0	0	0	1.00
Oncology Institute	1	0	3	1	2.80

Oncology Institute has a consensus target price of $6.50, indicating a potential upside of 149.04%. Given Oncology Institute’s stronger consensus rating and higher probable upside, analysts clearly believe Oncology Institute is more favorable than Pheton.

Profitability

This table compares Pheton and Oncology Institute’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pheton	N/A	N/A	N/A
Oncology Institute	-13.21%	-1,527.21%	-35.30%

Summary

Oncology Institute beats Pheton on 7 of the 13 factors compared between the two stocks.

About Pheton

Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.

About Oncology Institute

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.